In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates

Toxicology Letters

Volumn 188, Issue 2, 2009, Pages 98-103

  Olaharski, Andrew J ^a   Uppal, Hirdesh ^a   Cooper, Matthew ^a   Platz, Stefan ^a   Zabka, Tanja S ^b   Kolaja, Kyle L ^a  

^a Non Clinical Safety   (United States)

^b Non Clinical Safety Roche Palo Alto   (United States)

Author keywords

Bone marrow toxicity; CFC GEMM; Hematopoietic toxicity

Indexed keywords

DRUG;

ANIMAL CELL; ARTICLE; ASSAY; BONE MARROW; BONE MARROW TOXICITY; CELL LINEAGE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ERYTHROCYTE; GRANULOCYTE; HEMATOPOIETIC CELL; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SCREENING; STEM CELL;

ANIMALS; BONE MARROW; BONE MARROW CELLS; CELL LINEAGE; COLONY-FORMING UNITS ASSAY; HUMANS; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; TOXICITY TESTS;

EID: 67349138192     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.03.012     Document Type: Article

References (40)

1. Berth-Jones J. The use of ciclosporin in psoriasis. J. Dermatolog. Treat. 16 5-6 (2005) 258-277
2. Bradley T.R., and Metcalf D. The growth of mouse bone marrow cells in vitro. Aust. J Exp. Biol. Med. Sci. 44 3 (1966) 287-299
3. Burstein H.J., Storniolo A.M., Franco S., Forster J., Stein S., Rubin S., Salazar V.M., and Blackwell K.L. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann. Oncol. 19 6 (2008) 1068-1074
4. Cezar G.G. Can human embryonic stem cells contribute to the discovery of safer and more effective drugs?. Curr. Opin. Chem. Biol. 11 4 (2007) 405-409
5. Chabner B.A., and Young R.C. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J. Clin. Invest. 52 8 (1973) 1804-1811
6. Cohen M.H., Johnson J.R., Chen Y.F., Sridhara R., and Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10 7 (2005) 461-466
7. Cortes J., Kim D.W., Raffoux E., Martinelli G., Ritchie E., Roy L., Coutre S., Corm S., Hamerschlak N., Tang J.L., Hochhaus A., Khoury H.J., Brummendorf T.H., Michallet M., Rege-Cambrin G., Gambacorti-Passerini C., Radich J.P., Ernst T., Zhu C., Van Tornout J.M., and Talpaz M. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia (2008)
8. Dickler M.N., Cobleigh M.A., Miller K.D., Klein P.M., and Winer E.P. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res. Treat. (2008)
9. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., Powell B.L., Gabrilove J.L., Rousselot P., Reiffers J., Cornelissen J.J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J.L., Radich J.P., Simonsson B., Taylor K., Baccarani M., So C., Letvak L., and Larson R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355 23 (2006) 2408-2417
10. Dunton C.J. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 7 Suppl. 5 (2002) 11-19
11. Gribaldo L. Haematotoxicology: scientific basis and regulatory aspects. Altern Lab. Anim. 30 Suppl 2 (2002) 111-113
12. Gribaldo L., bBueren J., and Deldar A. The use of in vitro systems for evaluating hemotoxicity. ECVAM workshop report 14. Altern. Lab. Anim. 24 (1996) 211-231
13. Gribaldo L., Malerba I., Collotta A., Casati S., and Pessina A. Inhibition of CFU-E/BFU-E by 3′-azido-3′-deoxythymidine, chlorpropamide, and protoporphirin IX zinc (II): a comparison between direct exposure of progenitor cells and long-term exposure of bone marrow cultures. Toxicol. Sci. 58 1 (2000) 96-101
14. Hochhaus A., Baccarani M., Deininger M., Apperley J.F., Lipton J.H., Goldberg S.L., Corm S., Shah N.P., Cervantes F., Silver R.T., Niederwieser D., Stone R.M., Dombret H., Larson R.A., Roy L., Hughes T., Muller M.C., Ezzeddine R., Countouriotis A.M., and Kantarjian H.M. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22 6 (2008) 1200-1206
15. Kremer J.M., Bloom B.J., Breedveld F.C., Coombs J., Fletcher M.P., and Gruben D. A randomized double-blind placebo-controlled trial of 3 dose levels of CP-690 550 versus placebo in the treatment of acute rheumatoid arthritis. 70th Annual Science Meeting American College of Rheumatology, November 10-15, Washington DC (2006) Abstract L40
16. Kudlacz E., Perry B., Sawyer P., Conklyn M., McCurdy S., Brissette W., Flanagan And M., and Changelian P. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant. 4 1 (2004) 51-57
17. Lan Q., Zhang L., Li G., Vermeulen R., Weinberg R.S., Dosemeci M., Rappaport S.M., Shen M., Alter B.P., Wu Y., Kopp W., Waidyanatha S., Rabkin C., Guo W., Chanock S., Hayes R.B., Linet M., Kim S., Yin S., Rothman N., and Smith M.T. Hematotoxicity in workers exposed to low levels of benzene. Science 306 5702 (2004) 1774-1776
18. Medina P.J., and Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 30 8 (2008) 1426-1447
19. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., and Rini B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24 1 (2006) 16-24
20. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., Redman B.G., Margolin K.A., Merchan J.R., Wilding G., Ginsberg M.S., Bacik J., Kim S.T., Baum C.M., and Michaelson M.D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 21 (2006) 2516-2524
21. Nakagawa K., Tamura T., Negoro S., Kudoh S., Yamamoto N., Yamamoto N., Takeda K., Swaisland H., Nakatani I., Hirose M., Dong R.P., and Fukuoka M. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. 14 6 (2003) 922-930
22. Noel J.K., Crean S., Claflin J.E., Ranganathan G., Linz H., and Lahn M. Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature. Med. Oncol. 25 3 (2008) 323-330
23. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R., and Druker B.J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348 11 (2003) 994-1004
24. Orkin S.H., and Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132 4 (2008) 631-644
25. Parchment R.E., Gordon M., Grieshaber C.K., Sessa C., Volpe D., and Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann. Oncol. 9 4 (1998) 357-364
26. Pessina A., Albella B., Bayo M., Bueren J., Brantom P., Casati S., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Schoeters G., Sibiril Y., Van Den Heuvel R., and Gribaldo L. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol. Sci. 75 2 (2003) 355-367
27. Pluznik D.H., and Sachs L. The induction of clones of normal mast cells by a substance from conditioned medium. Exp. Cell. Res. 43 3 (1966) 553-563
28. Ray-Coquard I., Le Cesne A., Whelan J.S., Schoffski P., Bui B.N., Verweij J., Marreaud S., van Glabbeke M., Hogendoorn P., and Blay J.Y. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 13 4 (2008) 467-473
29. Rich I.N. High-throughput in vitro hemotoxicity testing and in vitro cross-platform comparative toxicity. Expert Opin. Drug Metab. Toxicol. 3 2 (2007) 295-307
30. Rich I.N., and Hall K.M. Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay. Toxicol. Sci. 87 2 (2005) 427-441
31. Rich I.N., and Kubanek B. The effect of reduced oxygen tension on colony formation of erythropoietic cells in vitro. Br. J. Haematol. 52 4 (1982) 579-588
32. Rock E.P., Goodman V., Jiang J.X., Mahjoob K., Verbois S.L., Morse D., Dagher R., Justice R., and Pazdur R. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12 1 (2007) 107-113
33. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin. Drug Saf. 4 2 (2005) 219-234
34. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabarbara P., and Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353 2 (2005) 123-132
35. Shim J.H., Park J.W., Choi J.I., Park B.J., and Kim C.M. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J. Cancer Res. Clin. Oncol. (2008)
36. Soverini S., Martinelli G., Iacobucci I., and Baccarani M. Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev. Anticancer Ther. 8 6 (2008) 853-864
37. Takimoto C.H., and Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother. Pharmacol. 61 4 (2008) 535-548
38. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M.A., Iyer V., Chen T.T., Huang F., Decillis A.P., and Sawyers C.L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354 24 (2006) 2531-2541
39. Weinblatt M.E., Kavanaugh A., Burgos-Vargas R., Dikranian A.H., Medrano-Ramirez G., Morales-Torres J.L., Murphy F.T., Musser T.K., Straniero N., Vicente-Gonzales A.V., and Grossbard E. Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58 11 (2008) 3309-3318
40. Widemann B.C., and Adamson P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist 11 6 (2006) 694-703